APR 22, 2015 07:54 AM PDT

Genetic Variance Explains Poor Response to Asthma Medications

WRITTEN BY: Ilene Schneider
3 25 1348
Researchers have identified a biological basis for asthmatic children who do not respond well to corticosteroid treatment - currently the most effective treatment for chronic asthma and acute asthma attack.
Effective treatment is either absent or incomplete in 40-70 percent of childhood asthma cases, researchers say.
Conducted at Cincinnati Children's Hospital Medical Center, the study also identifies a genetic pathway that could open the possibility of new therapies for difficult-to-treat patients. The findings are reported April 21 in The Journal of Allergy and Clinical Immunology, published by the American Academy of Allergy Asthma and Immunology.

The researchers performed genome-wide analysis of nasal epithelial cells collected from children experiencing acute asthma exacerbation. They compared genetic expression and medical responses in children who responded well to corticosteroids therapy to those who did not.

"Genome-wide analysis allowed us to identify a gene, VNN-1, whose expression discriminated between good and poor responders to systemic corticosteroid treatment," said Gurjit Khurana Hershey, MD, PhD, senior author and director of Asthma Research at Cincinnati Children's. "This may serve as a clinically useful biomarker to identify a subset of difficult-to-treat asthmatic children, and targeting the VNN-1 pathway may be useful as a therapeutic strategy."

Asthma affects close to 26 million people in the United States, 7 million of them children. Although people suffering from asthma share similar clinical symptoms, it is triggered by multiple genetic and environmental factors. This makes asthma a series of respiratory syndromes that can be difficult to study and treat and personalized therapeutic management is needed to achieve the best outcomes, according to the researchers.

Less-than-optimal management of childhood asthma is highlighted by the fact that nearly two-thirds of asthmatic children report at least one attack a year. And researchers estimate that effective treatment is either absent or incomplete in 40-70 percent of cases, highlighting the need for new treatment strategies. This includes the subset of children who do not respond well to systemic corticosteroid therapy.

"Difficult-to-treat patients account for over 50 percent of health care costs associated with asthma," Hershey said. "There are new drugs that may be helpful, as well as those that affect the VNN-1 pathway, but they have not been tested in asthma. This study provides the basis for a biomarker to determine which patients might be best to target with new treatments."

The study included 57 children between ages 5 and 18 who were admitted through the Emergency Department at Cincinnati Children's and hospitalized for treatment of their asthma. In an initial group of patients experiencing asthma attack, nasal epithelia cells were collected and tested for comparative VNN-1 expression. Researchers then tested a second group of patients to verify results of the first group.

Starting with a candidate list of 20,000 genes, researchers screened down to eight before singling out VNN-1 as the primary target. They conducted a series of cell biology tests in the lab to show that VNN-1 expression is required for inhaled corticoids to work during asthma attack. In cells from patients whose asthma did not respond well to treatment, researchers found a biochemical variation in the VNN-1 molecular network that hindered its expression.

The researchers next tested and confirmed their clinical findings in laboratory mouse models of asthma, and produced data suggesting that targeting the VNN-1 pathway therapeutically might be a way to improve outcomes for difficult-to-treat asthmatic children.

Testing continues in laboratory models to better determine the VNN-1 pathway's role in contributing to airway inflammation and hyper-responsiveness in asthma. Researches are also testing drugs that target the VNN-1 pathway to determine which, if any, might improve treatment for asthmatic children who do not respond to current treatments.

Enhanced expression of VNN-1 is associated with multiple human diseases, such as inflammatory bowel disease, immune thrombocytopenia and system lupus erythematosus. This is the first study to report improperly regulated expression of VNN-1 and its mRNA (which help translate and transmit genetic information) in asthma.

Source: Cincinnati Children's Hospital Medical Center
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUN 21, 2018
Clinical & Molecular DX
JUN 21, 2018
Unique Gene Signature in the Blood Indicates TB Diagnosis
A unique series of genes could tell doctors that a person will develop a tuberculosis (TB) infection months before symptoms are visible. From The Francis C
JUN 28, 2018
Genetics & Genomics
JUN 28, 2018
Many Psychiatric Disorders Share Genetic Features
This work presents a different way of classifying, and potentially, treating psychiatric disorders.
JUL 07, 2018
Genetics & Genomics
JUL 07, 2018
Cause of Gender Differences in Neurodevelopmental Disorders is ID'ed
Gender is a known factor in the development of neurological disorders. Now scientists think they know why.
JUL 21, 2018
Videos
JUL 21, 2018
The UK's First '3 Person Baby'
Mitochondria carry their own genetic material, which is only inherited from mom.
AUG 01, 2018
Videos
AUG 01, 2018
Award-winning Images of Organoids From the Koch Institute
Every year, the Koch Institute at MIT shares some of the most stunning images produced at the research facility.
AUG 11, 2018
Videos
AUG 11, 2018
GMO Crop Ban Rescinded
Genetically modified crops that use neonic pesticides can now be planted in wildlife refuges.
Loading Comments...